Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
20 juin 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
RANDOLPH, Mass. and CAMBRIDGE, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics (Nasdaq: FULC) announce the launch of Project Mercury, a...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 juin 2023 16h54 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
15 mai 2023 07h05 HE
|
Fulcrum Therapeutics, Inc.
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD)...
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
15 mai 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
— Industry veteran brings more than 20 years of experience; will assume role effective July 1st — — During transition period Mr. Sapir will serve as special advisor to the interim CEO and president...
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
08 mai 2023 16h05 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 mai 2023 18h06 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces CFO Resignation
05 avr. 2023 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mars 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
09 mars 2023 07h00 HE
|
Fulcrum Therapeutics, Inc.
― Company is working to address clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle cell disease ― ― FTX-6058 data from 12 mg cohort of Phase...